This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Vansen Pharma Inc.
Drug Names(s): gemifloxacin mesylate
Merus Labs would not disclose the quarterly sales for Q1 2012 nor Q3 2012 (Q2 2012 $0.5MM, Q4 2012 $0.7MM). Per the company’s Feb 2013 corporate presentation, net sales for 2012 were $2.7MM. However, the representative stated that as of Q4 2012, revenues will be disclosed.
The active ingredient of Factive is gemifloxacin, an antibiotic of the quinolone family. It acts by inhibiting DNA synthesis through the inhibition of both DNA gyrase (a type II topoisomerase) and topoisomerase IV (TOPO IV), enzymes essential for bacterial DNA processing and organism growth.
GeneSoft and LG
After the merger of SmithKline Beecham and Glaxo Wellcome, GSK returned all rights to Factive developer LG Life Sciences of Seoul, Korea. Genesoft acquired North American and European rights from LG in October 2002.
Oscient (Genome and Genesoft) and LG
Genome Therapeutics and Genesoft Pharmaceuticals merged to form Oscient Pharmaceuticals. Oscient Pharmaceuticals amended its license and option agreement with LG Life Sciences for Factive. The amended agreement includes a reduction of future royalties payable to LG Life Sciences at certain Factive revenue levels in territories covered by the agreement.
While specific terms are not disclosed, as part of the amended agreement the Company will make a one time cash payment of $2 million to LG Life Sciences, recorded in the first quarter of 2005. The modified agreement calls for an $8 million increase in milestone payments to LG Life Sciences, which are payable as certain salesthresholds for Factive...See full deal structure in Biomedtracker
Partners: LG Life Sciences Ltd. The Menarini Group
Pink Sheet GSK Factive
Pink Sheet GSK returns gemifloxacin rights
Additional information available to subscribers only: